ArticleBMJ (Clinical research ed.)1989
Soluble interleukin 2 receptor in atopic eczema.
Article in BMJ (Clinical research ed.), 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Guidelines on the use of extracorporeal photopheresis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2014Guideline
- Clinical Efficacy of Nutritional Supplements in Atopic Dermatitis: Systematic Review.JMIR dermatology · 2023Review
- European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Modulation of Immune Functions by Foods.Evidence-based complementary and alternative medicine : eCAM · 2004Article
- Reduced interferon-gamma (IFN-gamma) secretion with increased IFN-gamma mRNA expression in atopic dermatitis: evidence for a post-transcriptional defect.Clinical and experimental immunology · 1994Article
- Spontaneous expression of IL-4 mRNA in lymphocytes from children with atopic dermatitis.Clinical and experimental immunology · 1994Article
- Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis.The Journal of clinical investigation · 1994Article
- Soluble interleukin-2 receptors in ulcerative colitis.Mediators of inflammation · 1993Article
- Interleukin-1 alpha and soluble interleukin-2 receptor in atopic dermatitis.Archives of disease in childhood · 1992Article
- Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis.Archives of dermatological research · 1992Article
- Immunopathology of atopic dermatitis.Springer seminars in immunopathology · 1992Review
- The interleukin-2 receptor in lesions and serum of bullous pemphigoid.Archives of dermatological research · 1992Article
- Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.Clinical and experimental immunology · 1991Article
- In vivo and in vitro effects of glucocorticoids on lectin-induced blastogenesis in atopic dermatitis.Archives of dermatological research · 1991Article
- Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.Clinical and experimental immunology · 1990Article
- Article
- Interleukin 2, soluble interleukin 2 receptor, and interferon-gamma in the suction blister fluids from psoriatic skin.Archives of dermatological research · 1990Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether serum soluble interleukin 2 receptor concentrations are related to disease activity in atopic eczema.
designSingle cohort longitudinal study with controls.
settingOutpatient and general medicine departments in secondary referral centre. PATIENTS: Of 15 patients aged 17-57 with severe atopic eczema, all with acute exacerbations of disease, 13 were admitted to hospital and two treated as outpatients until the skin lesions had resolved or greatly improved. Nineteen controls gave single blood samples.
interventionsDaily skin dressing with betamethasone valerate (0.025%) and ichthammol paste and tubular dressings. END POINT: Resolution of or considerable improvement in skin lesions. MEASUREMENTS AND MAIN
resultsEnzyme linked immunosorbent assays (ELISA) were used to measure serum soluble interleukin 2 receptor concentrations in blood samples taken on admission, at intervals subsequently, and on discharge. Clinical scores of disease activity were also made. Median concentrations on admission were significantly higher (770 U/ml) in the patients than the controls (300 U/ml). Concentrations fell significantly during treatment. In 25 assessments made at different times in 13 patients serum soluble interleukin 2 receptor concentration correlated significantly (R = 0.73) with clinical disease activity.
conclusionsCellular immunopathogenic mechanisms contribute to atopic eczema. Immune activation can be measured in atopic eczema by measurements of soluble interleukin 2 receptor, and this should facilitate assessment of response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.